Project
Overactive bladder (OAB) syndrome - new technique improves patient outcomes
King's Health Partners Uro-oncology Group
KCL researcher Professor Dasgupta, along with colleagues at University College London and Imperial College London, identified that certain receptors within nerve fibres in the bladder were present at abnormal levels in OAB syndrome. These could be suppressed using Botulinum Toxin-A, introduced into the bladder under local anaesthetic, removing the need for an overnight hospital stay.
This cost-effective OAB therapy is now licensed by the EU and FDA, is recommended in national and international guidelines, and has significantly improved the treatment of a common health problem.